[Total review of all results collected worldwide with astemizole (Hismanal)].
From the start of the Astemizole clinical investigations, until now the results of 39 trials including more than 2300 patients are available. These results show that Astemizole is an effective and safe Histamine-H1-antagonist for the therapy of hayfever, chronic allergic rhinitis, allergic conjunctivitis, chronic urticaria and allergic bronchitis in adults and children. Astemizole was superior to placebo and the classical antihistamines like Clemastine, Terfenadine, Ketotifen, Mequitazine, pheniramine and Chlorphenamine.
Rombaut
N
N
Vanden Bussche
G
G
D016589:Astemizole; D001507:Beclomethasone / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D014581:Urticaria / Q000188:drug therapy
D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D016589:Astemizole; D001507:Beclomethasone
Gesamtübersicht über alle weltweit gewonnenen Ergebnisse mit Astemizol (Hismanal).